{"id":"NCT00243243","sponsor":"United States Army Institute of Surgical Research","briefTitle":"Effect of rFVIIa on Peri-operative Blood Loss in Patients Undergoing Major Burn","officialTitle":"Effect of Recombinant Coagulation Factor VIIa on Peri-operative Blood Loss in Patients Undergoing Major Burn Excision and Grafting","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-01","primaryCompletion":"2011-06","completion":"2011-07","firstPosted":"2005-10-21","resultsPosted":"2013-03-06","lastUpdate":"2016-05-26"},"enrollment":20,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Burns"],"interventions":[{"type":"DRUG","name":"Recombinant Factor VIIa","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"rFVIIa","type":"EXPERIMENTAL"},{"label":"Control","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of the study is to see if a medication (Recombinant Coagulation Factor VIIa or NovoSeven), normally used to stop bleeding in persons with a bleeding disorder, will lower the amount of blood lost during burn surgery.","primaryOutcome":{"measure":"Total Number of Blood Components Transfused During and up to 24 Hours Post Operatively","timeFrame":"24 hours","effectByArm":[{"arm":"Experimental","deltaMin":68.9,"sd":null},{"arm":"Control- Placebo","deltaMin":87.2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":12},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["12458988"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":10},"commonTop":["Infection","Hypotension","Pleural Effusion","Decreased Oxygen Saturation","Liver Injury"]}}